SVB Securities analyst Marc Goodman initiated coverage with a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $24.00. The company’s shares closed yesterday at $19.20.
According to TipRanks, Goodman is a 3-star analyst with an average return of 2.4% and a 48.06% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Biogen, and Marinus.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biohaven Ltd. with a $24.00 average price target, representing a 25.00% upside. In a report released on January 10, Piper Sandler also maintained a Buy rating on the stock with a $21.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $20.00 and a one-year low of $5.54. Currently, Biohaven Ltd. has an average volume of 1.12M.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BHVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Read More on BHVN:
- Piper ‘incrementally positive’ on Biohaven shares after BHV-7000 data
- J.P. Morgan Says These 2 Stocks Are Ready to Rip Higher — This Is What Makes Them Attractive Buys
- Biohaven rises 9.0%
- Biohaven initiated with an Overweight at JPMorgan
- Biohaven treatment of spinal muscular atrophy granted orphan designation
